Nonpeptide angiotensin II receptor antagonists: potential advantages over ACE inhibitors.
Brooks
D P
DP
Department of Renal Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406-0939.
DePalma
P D
PD
Fredrickson
T A
TA
Spielman
W S
WS
Ruffolo
R R
RR
D000179:Acrylates / Q000633:toxicity*; D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000503:physiopathology; D000803:Angiotensin I / Q000494:pharmacology; D000804:Angiotensin II / Q000378:metabolism*; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000633:toxicity*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000633:toxicity; D003371:Cough / Q000139:chemically induced* / Q000503:physiopathology; D004285:Dogs; D004656:Enalapril / Q000633:toxicity; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D007093:Imidazoles / Q000633:toxicity*; D008297:Male; D012079:Renal Circulation / Q000187:drug effects; D013876:Thiophenes
D000179:Acrylates; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D007093:Imidazoles; D013876:Thiophenes; D000804:Angiotensin II; C068373:eprosartan; D004656:Enalapril; D000803:Angiotensin I; D002216:Captopril